Can you take Sermorelin and Tesamorelin together?

There is no specific, well-documented interaction rule for combining Sermorelin and Tesamorelin in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Sermorelin or Tesamorelin?

Sermorelin is currently fda-approved and Tesamorelin is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

Sermorelin vs Tesamorelin

Q: What is the difference between Sermorelin and Tesamorelin?

Sermorelin: Sermorelin is a synthetic analog of the first 29 amino acids of GHRH (Growth Hormone-Releasing Hormone). It was FDA-approved for pediatric GH deficiency diagnosis and is widely used off-label in anti-aging and performance medicine. It stimulates pulsatile GH release more physiologically than exogenous GH. Tesamorelin: Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Sermorelin

FDA-approved

Sermorelin is a synthetic analog of the first 29 amino acids of GHRH (Growth Hormone-Releasing Hormone). It was FDA-approved for pediatric GH deficiency diagnosis and is widely used off-label in anti-aging and performance medicine. It stimulates pulsatile GH release more physiologically than exogenous GH.

Full profile

Tesamorelin

FDA-approved

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat.

Full profile

	Sermorelin	Tesamorelin
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	GHRH 1-29, GRF 1-29 NH2, Geref	Egrifta, Egrifta SV, TH9507, GHRH analog
Evidence	FDA-approved	FDA-approved
Dosing range	100mcg–500mcg mcg, once daily (before sleep)	1.28mg–2mg mg, once daily (subcutaneous)
Administration	Subcutaneous injection	Subcutaneous injection (abdomen, with site rotation)
Key side effects	Injection site redness, Headache, Flushing, Dizziness	Injection site reactions (erythema, pruritus), Peripheral edema, Arthralgia (joint pain), Myalgia
Cited sources	1 reference	5 references

Key differences

Administration: Sermorelin — Subcutaneous injection; Tesamorelin — Subcutaneous injection (abdomen, with site rotation).
Dosing units differ: Sermorelin is dosed in mcg, Tesamorelin in mg — they operate at different scales.
Frequency: Sermorelin is typically once daily (before sleep); Tesamorelin is once daily (subcutaneous).
Research depth: this profile cites 1 source for Sermorelin vs 5 for Tesamorelin.

How each works

Sermorelin

Sermorelin works by binding pituitary GHRH receptors to stimulate GH secretion within the body's natural feedback loop. Unlike synthetic GH, it does not suppress endogenous production. Clinical studies show improved body composition, sleep quality, and IGF-1 levels in GH-deficient adults. Its short half-life (~10 min) means it requires daily dosing.

Tesamorelin

Tesamorelin stimulates pulsatile growth hormone (GH) release from the pituitary, raising serum IGF-1 and preferentially reducing visceral adipose tissue (VAT). FDA-registration trials (Falutz et al., NEJM 2007; JAIDS 2010) showed ~15% VAT reduction versus placebo over 26 weeks. Later randomized trials (Stanley et al., JAMA 2014; Lancet HIV 2019) extended the evidence to liver fat, showing meaningful reductions in hepatic fat fraction and attenuated fibrosis progression in HIV-associated NAFLD.

Read the full Sermorelin profile Read the full Tesamorelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.